Dr. Shayma Kazmi, from Cancer Treatment Centers of America, on Olanzapine for Breakthrough Chemotherapy-Induced Nausea and Vomiting
The University of Virginia Cancer Center has developed a new method for delivering radiation therapy along with less invasive surgery in a more precise and personalized manner.
My path to becoming an oncologist was a little different from most, but like so many others, I was inspired by a practicing physician who showed me what medicine truly can be.
Shebli Atrash, MD, discusses the development and current use of BCMA-targeted antibody-drug conjugates and CAR T-cell therapies for the treatment of patients with multiple myeloma.
The healthcare system in the United States has become increasingly unsustainable.
When my alarm goes off at 5:30 am, I wake up prepared to play many roles. Juggling family life with 2 young children, caring for my patients as a fellow, and pursuing scholarly activities leaves little free time.
A feasibility study of a smartphone application that patients undergoing radiation therapy for head and neck cancer can use to regularly report mucositis symptoms.
Celebration at the end of cancer treatment is often premature.
Shella Saint Fleur-Lominy, MD, PhD, discusses targeted pathways in myeloproliferative neoplasms.
Given the widespread financial impact the high cost of cancer drugs has on the healthcare system, it may be time for the FDA to take a broader approach when reviewing oncology drug applications. By also examining the cost of the drug, the FDA could shine a light on escalating drug costs and play a leadership role in creating new programs and initiatives that help patients pay for promising new therapies.
Sherene Loi, MD, PhD, on the association between immune cells and a pathologic complete response in patients with breast cancer after being given chemotherapy and trastuzumab.
Sheri Holmen, PhD, investigator, Associate Professor in the Department of Surgery, Adjunct Professor in the Department of Oncological Sciences, Huntsman Cancer Institute, the University of Utah School of Medicine, discusses understanding drivers for melanoma metastasis.
Basal cell carcinoma (BCC) is the most common human malignancy and by far the most prevalent form of skin cancer, accounting for more than 80% of all cases.
Shikha Jain, MD, FACP, discusses the push toward personalized treatment approaches in colorectal cancer with liver metastases.
The expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.
Whether it be to identify a seemingly frail older patient with metastatic colon cancer who would tolerate and benefit from standard treatment, or to prevent a frail older lung cancer patient from experiencing severe side effects due to adjuvant chemotherapy, oncologists are having to make difficult decisions with increasing frequency.
Dr. Shirish Gadgeel discusses the activity of antibody drug conjugates against brain metastases in non-small cell lung cancer based on emerging data, suggesting superiority over chemotherapy.
Shirish M. Gadgeel, MD, MBBS, Mary Lou Kennedy Research Professor in Thoracic Oncology, professor, Department of Internal Medicine, Division of Hematology/Oncology, co-leader, Thoracic Oncology Research Program, and associate director, Networking and Affiliated Centers, University of Michigan Medicine, discusses the utility of liquid biopsies in lung cancer.
Closing out their discussion on HR+ breast cancer management, expert panelists share their excitement for the evolving treatment paradigm.
Clifford Chirls discusses the features of the new social networking site iMedExchange and explains how it diff ers from other social networking resources for physicians.
Shiven B. Patel, MD, MBA, FACP, discusses treatment considerations in patients with advanced squamous non–small cell lung cancer.
Shlomo Koyfman, MD, associate staff, radiation oncology, Cleveland Clinic, discusses reirradiation options for patients with head and neck cancer.
Shoba A. Navai, MD, an assistant professor, Department of Pediatrics, Section of Pediatric Hematology and Oncology, at Baylor College of Medicine, Texas Children’s Hospital, discusses treatment options for patients with relapsed/refractory sarcoma.
Shota Fukuoka, MD, physician, National Cancer Center in Japan, discusses finding the recommended dosage of regorafenib plus nivolumab in patients with advanced gastric cancer or colorectal cancer.